To assess mortality and In-Patient Outcomes in TM patients from 2006 to 2021.

Studies reporting mortality and in-patient trends in Transverse Myelitis (TM) are inconsistent and the data on race and gender sub-categorization is limited.

This is a retrospective analysis of Transverse Myelitis (TM) (N=13848) hospitalizations from 2006 to 2021 using National Inpatient Sample database. We performed survey-weighted logistic and linear regression models to assess the mortality, discharge disposition and length of stay predictors considering variables age, race, gender and comorbidities.

Out of 131,367,025 patients, 13,848 were admitted for TM. Mean age was 50.48 (95% CI:50.08-50.88), average LOS 9.52 days(95% CI: 9.30 - 9.75) and total mortality was 1.88% among TM patients. In-mortality was 0.79%(95% CI: 0.48% - 1.32%), 1.18% (95% CI: 0.91% - 1.53%) and 2.91% (95% CI: 2.48% - 3.41%) for age groups <30, 31-55, 55< respectively (p<0.05). Total mean cost was $95415.87($92,423.00 - $98,408.74).  Logistic regression analysis showed increasing age increased the odds of mortality by 2.8% (OR: 1.028, 95% CI: 1.017 - 1.038, p < 0.001). Teaching hospital status increased (p=0.003), while older age and longer LOS decreased (p<0.001), the odds of home discharge. Elixhauser comorbidity scores raised in hospital mortality odds by 27.8% per unit increase (OR: 1.278, 95% CI: 1.205 - 1.356, p < 0.001). Regression for LOS showed each year of age decreased LOS by 0.07 days (95% CI: -0.0840 to -0.0553, p<0.001). Racial disparities in LOS were observed: White patients had a mean LOS of 8.81 days (95% CI: 8.55 - 9.06), while Black (10.38 days, 95% CI: 9.83 - 10.94, p=0.008), Hispanic (10.75 days, 95% CI: 9.89 - 11.62, p<0.001), Asian/Pacific Islander (10.94 days, 95% CI: 9.56 - 12.32, p=0.025), and Other race (11.26 days, p=0.046).